Chikungunya: Symptoms, Prevention, and What to Know in 2026

Chikungunya: Symptoms, Prevention, and What to Know in 2026

You pack for a long-awaited trip to the Caribbean, careful to bring everything—passport, sunscreen, comfortable shoes. You might not think about a tiny daytime mosquito. Yet for a growing number of travellers, that one mosquito bite leads to weeks of debilitating joint pain and fever long after the holiday photos are posted.

So what is chikungunya exactly? Chikungunya is a viral disease spread by infected Aedes mosquitoes. It causes a sudden high fever and severe joint pain that can become chronic, lasting for months or even years. There is no specific antiviral treatment, so prevention through mosquito bite avoidance is essential.

Medical disclaimer
Not medically reviewed. This article was editorially fact-checked and is for educational purposes only. It does not replace professional medical advice. If you develop sudden fever and severe joint pain after travel to a risk area, seek medical evaluation.

Quick summary

• Chikungunya is caused by the chikungunya virus (CHIKV), transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes—the same species that spread dengue and Zika.

• The disease is now found in over 110 countries across Africa, Asia, the Americas, and parts of Europe, with ongoing outbreaks reported globally in 2025 and 2026.

• There are no medicines to treat the virus itself; care focuses on relieving fever and pain with rest, fluids, and paracetamol (acetaminophen).

• The hallmark symptom is sudden, often debilitating joint pain that may persist for months to years in a significant proportion of cases.

• Prevention relies entirely on avoiding mosquito bites, as no widely available vaccine is currently in use following safety concerns.

Key Takeaway

Chikungunya cannot be treated with specific antiviral drugs. The only reliable protection is preventing mosquito bites. If you travel to a region where chikungunya is present—including parts of the Americas, Africa, Asia, and Europe—use EPA-registered insect repellent, wear protective clothing, and stay in air-conditioned or screened spaces. If you develop fever and severe joint pain after travel, see a healthcare provider promptly.

Main explanation: What is chikungunya?

Chikungunya virus (CHIKV) is an alphavirus first isolated in Tanzania in 1952. The name comes from the Kimakonde language of southern Tanzania, meaning "that which bends up," describing the contorted posture of people suffering from severe joint pain.

The virus is transmitted when an infected female Aedes mosquito bites a person. Once in the bloodstream, the virus replicates rapidly, causing an abrupt onset of symptoms. Aedes mosquitoes bite primarily during daylight hours, which is a key difference from malaria-carrying Anopheles mosquitoes that bite at night.

After an infected mosquito bite, symptoms typically begin after an incubation period of 3–7 days (range 1–12 days). Most infected people become symptomatic.

The two phases of illness

Acute phase (first 7–10 days)

The acute phase is characterised by a sudden high fever (often above 39°C or 102°F) and severe joint pain. Other common symptoms include:

• Headache

• Muscle pain (myalgia)

• Joint swelling

• Rash (maculopapular, often on the trunk and limbs)

• Nausea and vomiting

• Fatigue

• Conjunctivitis (red eyes)

Acute symptoms typically resolve within 7–10 days.

Chronic phase (persistent symptoms)

For many patients, the illness does not end when the fever subsides. Chronic joint pain can last for months or years. Data from a systematic review and meta-analysis found that 43% of chikungunya patients did not recover after three months.

Long-term symptoms are typically symmetric joint pain affecting the wrists, hands, ankles, and knees, often accompanied by morning stiffness and joint swelling. The histopathological changes in the synovial tissue resemble those seen in rheumatoid arthritis.

One study followed patients for three years after acute infection and found that 60% experienced arthralgia (joint pain) during that period. Most reported episodic relapse and recovery, with pain often highly incapacitating.

Who is at highest risk for severe disease?

While anyone can be infected, certain groups face higher risks of severe outcomes:

• Newborns infected around the time of birth

• Older adults (age 65 years and older)

• People with underlying medical conditions, including hypertension, diabetes, or cardiovascular disease

Severe complications are rare but can include myocarditis, hepatitis, meningoencephalitis, Guillain-Barré syndrome, and haemorrhage. Mortality is uncommon and occurs mostly in older adults or those with coexisting health problems.

What causes or contributes to the issue

How transmission works

1. An uninfected Aedes mosquito bites a person who has chikungunya virus circulating in their blood.

2. The mosquito ingests the virus, which replicates in the mosquito over several days and moves to its salivary glands.

3. The infected mosquito then bites another person, transmitting the virus.

4. The newly infected person develops high concentrations of the virus in their blood during the first week of illness, potentially infecting more mosquitoes and continuing the cycle.

Aedes mosquito behaviour

These mosquitoes are aggressive daytime biters. Aedes aegypti feeds both indoors and outdoors, while Aedes albopictus (the Asian tiger mosquito) feeds primarily outdoors. Both species lay eggs in containers with standing water—anything from flowerpots and discarded tyres to birdbaths and bottle caps.

Global spread

As of December 2024, local transmission of chikungunya had been reported from 119 countries and territories across six WHO regions. Another 27 countries have established populations of competent Aedes aegypti mosquitoes but have not yet reported local transmission—meaning the virus could arrive at any time.

In 2025, a global resurgence was noted. Between January and September 2025, 445,271 suspected and confirmed cases and 155 deaths were reported from 40 countries. In Europe, chikungunya is not endemic, but sporadic local transmission has occurred when infected travellers return and are bitten by local Aedes mosquitoes, particularly during warmer months.

Climate change and urbanisation

Drivers of increased transmission include the expanded geographic distribution of Aedes mosquitoes (linked to transportation and climate change), unplanned urbanisation, poor water management, and weakened vector surveillance and control programmes.

What readers can safely do (prevention)

The best way to protect yourself from chikungunya is to prevent mosquito bites entirely.

Before travel

• Check CDC, WHO, or ECDC maps to see if your destination has ongoing chikungunya transmission.

• If you are in a higher-risk group (older adults, pregnant women, people with chronic conditions), consider avoiding travel to areas with active outbreaks.

• Discuss vaccination options with your healthcare provider (see vaccine note below).

During travel

• Use insect repellent: Choose an EPA-registered repellent containing DEET, picaridin, IR3535, oil of lemon eucalyptus (OLE), para-menthane-diol (PMD), or 2-undecanone. Apply according to label instructions.

• Wear protective clothing: Long-sleeved shirts and long pants. For additional protection, treat clothing and gear with 0.5% permethrin.

• Choose lodging wisely: Stay in places with air conditioning or window and door screens. Use a mosquito net if sleeping outdoors.

• Eliminate standing water: Empty, scrub, or cover any containers that can hold water around your accommodation (flowerpots, buckets, tyres).

After travel (if you develop symptoms)

If you are suspected or confirmed to have chikungunya, prevent further mosquito bites during your first week of illness. During this period, the virus is present in your blood, and a mosquito biting you can become infected and spread the virus to other people.

What to do if you are diagnosed

• Rest and stay well-hydrated.

• Take paracetamol (acetaminophen) to reduce fever and relieve pain.

• Do not take aspirin, ibuprofen, or other NSAIDs until dengue has been ruled out, as these can increase the risk of bleeding in people who actually have dengue (which can initially look very similar).

• Follow up with your healthcare provider if joint pain persists beyond the acute phase.

A note on vaccines

As of early 2026, the chikungunya vaccine landscape is complex. In November 2023, the FDA approved Ixchiq, a live attenuated vaccine, for adults at increased risk of chikungunya exposure. However, following post‑marketing reports of serious adverse events—including chikungunya‑like illness, hospitalisations, encephalitis and deaths—the FDA suspended its biologics license in August 2025.

At present, no chikungunya vaccine is widely available for routine use. Another vaccine candidate, Vimkunya (a virus‑like particle vaccine), has received approvals in some regions, but widespread availability remains limited. For the most current information on vaccine availability in your country, consult your healthcare provider or local public health authority before travel.

Because the vaccine situation is evolving rapidly, you should not rely on vaccination as your primary prevention strategy. Mosquito bite prevention remains the cornerstone of protection.

Common mistakes to avoid

1. Assuming mosquitoes only bite at night. Aedes mosquitoes bite during the day, especially early morning and late afternoon. Do not skip repellent during daylight hours.

2. Mistaking chikungunya for dengue or a bad flu. Symptoms overlap significantly, but management differs—especially regarding NSAID use. Always see a healthcare provider for proper diagnosis.

3. Believing you are safe if you have had chikungunya once. A single infection provides long‑term immunity, but travellers who have never been infected remain fully susceptible.

4. Thinking drinking unsafe water causes infection. Chikungunya is mosquito‑borne, not water‑borne. You cannot catch it from swimming, drinking, or food.

5. Ignoring persistent joint pain after acute illness. Chronic arthralgia is common and can be disabling. Seek medical follow‑up; physical therapy and pain management strategies may help.

Biology made simple

Chikungunya virus is an RNA virus—its genetic material is RNA rather than DNA. After a mosquito bite, the virus travels through the bloodstream and invades cells, particularly targeting cells in the joints, muscles, and skin.

The virus triggers a powerful inflammatory response. Your immune system releases signalling proteins called cytokines, which cause fever, pain, and swelling. In most viral infections, the immune system clears the virus within days. But in chikungunya, pieces of the virus or viral genetic material can persist in joint tissues for months, keeping the inflammatory system activated. This explains why joint pain continues long after the fever is gone.

Some researchers believe the chronic pain may also involve an autoimmune component—where the immune system mistakenly attacks the body's own joint tissues after being triggered by the virus.

One realistic scenario (composite example)

A 52‑year‑old woman travels to Brazil for a family wedding in February 2026. She stays in a rented house with open windows and notices mosquitoes during the day but does not use repellent. Five days after returning to Canada, she develops a sudden fever of 39.5°C (103°F), severe pain in her wrists and ankles, and a rash on her torso. Her family doctor orders blood tests; RT‑PCR is positive for chikungunya virus. She is advised to rest, take paracetamol, and avoid NSAIDs until dengue is ruled out. The fever resolves after six days, but the joint pain persists. Three months later, she continues to experience morning stiffness and hand pain, requiring referral to a rheumatologist.

This fictional example illustrates the typical course—acute illness followed by potentially prolonged joint symptoms—and the importance of appropriate diagnosis and follow‑up.

Myth vs Fact

When to see a doctor

Seek medical attention if you have:

• Fever with severe joint pain within two weeks of travelling to a region with chikungunya (or known mosquito exposure in a risk area)

• Symptoms that interfere with your ability to move or perform daily activities

• Fever in a newborn, older adult, or person with underlying health conditions

Go to an emergency department (A&E / ER) if you experience:

• Difficulty breathing

• Persistent vomiting or inability to keep fluids down

• Confusion, seizures, or neurological symptoms

• Signs of bleeding (unexplained bruising, bleeding gums, blood in vomit or stool)

Questions to ask your doctor

1. "Based on my travel history and symptoms, should I be tested for chikungunya, dengue, and Zika? What specific tests (RT‑PCR, IgM) are most appropriate given how long I have been sick?"

2. "I have persistent joint pain two months after acute illness. What treatments or therapies—such as physical therapy, NSAIDs, or other medications—are safe and effective for post‑chikungunya arthritis?"

3. "I am planning travel to a chikungunya risk area. What is the latest information on vaccine availability, and what mosquito prevention measures should I prioritise given my health profile?"

5 FAQs

1. Is there a cure for chikungunya?
No specific antiviral treatment exists. Most people recover fully with rest, hydration, and fever‑reducing medication. However, chronic joint pain can persist for months to years in a significant proportion of cases.

2. How long does chikungunya last?
Acute symptoms typically resolve in 7–10 days. But joint pain may continue for weeks, months, or even years. Studies show 43% of patients had not recovered after 3 months.

3. Can I get chikungunya more than once?
No. A single chikungunya infection provides long‑lasting immunity. You cannot be reinfected with the same virus.

4. What is the difference between chikungunya and dengue?
Both are transmitted by the same Aedes mosquitoes and cause fever and pain. Chikungunya more often causes severe, prolonged joint pain. Dengue carries a risk of bleeding and low platelet counts, requiring different management (especially avoiding NSAIDs until ruled out).

5. Should I cancel my trip if there is a chikungunya outbreak?
For most healthy travellers, no—but you should take mosquito bite prevention very seriously. If you are an older adult, have chronic health conditions, or are pregnant, discuss with your healthcare provider whether travel is advisable.

Written by:
Ibrahim Abdo, Health Content Specialist and Evidence‑Based Medical Writer focused on translating complex health information into clear, trustworthy, reader‑friendly insights.

Medical review status:
Not medically reviewed. This article was editorially fact‑checked and is for educational purposes only.

Published: April 29, 2026
Last updated: April 29, 2026

Editorial standard:
This article was created using evidence‑based sources and reviewed for clarity, accuracy, and reader safety.

Sources

1. CDC. "Clinical Signs and Symptoms of Chikungunya Virus Disease." https://www.cdc.gov/chikungunya/hcp/clinical-signs/. Updated August 20, 2025.
   Supports: incubation period, symptoms, risk groups, duration, complications.

2. CDC. "Symptoms, Diagnosis, & Treatment." https://www.cdc.gov/chikungunya/symptoms-diagnosis-treatment/. Updated November 19, 2025.
   Supports: common symptoms, risk groups, treatment guidance (paracetamol only, avoid NSAIDs until dengue excluded).

3. CDC. "Treatment and Prevention of Chikungunya Virus Disease." https://www.cdc.gov/chikungunya/hcp/treatment-prevention/. Updated February 19, 2026.
   Supports: supportive treatment, prevention measures for travellers, vaccine recommendation context.

4. CDC. "Preventing Chikungunya." https://www.cdc.gov/Chikungunya/prevention/. Updated December 16, 2025.
   Supports: mosquito bite prevention strategies (repellent, clothing, permethrin, lodging).

5. WHO. "Chikungunya fact sheet." https://www.who.int/en/news-room/fact-sheets/detail/chikungunya. Updated April 14, 2025.
   Supports: transmission, symptoms, global distribution, name origin.

6. WHO. "Chikungunya virus disease – Global situation." https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON581. Published October 3, 2025.
   *Supports: 2025 global case counts (445,271 suspected/confirmed, 155 deaths), 119 affected countries, drivers of spread.*

7. ECDC. "Chikungunya virus disease worldwide overview." Situation update, March 2026. https://www.ecdc.europa.eu/en/chikungunya-monthly. Accessed April 29, 2026.
   Supports: 2026 case data (32,758 cases, 9 deaths as of February 2026), ongoing outbreaks.

8. ECDC. "Chikungunya virus disease risk assessment for mainland EU/EEA." https://www.ecdc.europa.eu/en/chikungunya/surveillance-and-updates/risk-assessment. Updated May 2, 2025.
   Supports: European context, Aedes albopictus establishment, temperature‑dependent transmission risk.

9. NCBI / StatPearls. "Chikungunya Fever." https://www.ncbi.nlm.nih.gov/books/NBK534224/. Updated June 26, 2023.
   Supports: virology, vectors, history, chronic arthritis.

10. ScienceDirect (Seminars in Arthritis and Rheumatism). "Chikungunya and other viral arthritis." 2025. https://www.sciencedirect.com/science/article/abs/pii/S1521694225000361.
    Supports: 20–40% chronic pain rate, autoimmune mechanisms.

11. Valneva / Ixchiq HCP site. "Symptoms of Chikungunya." https://ixchiq.ca/hcp/symptoms-of-chikungunya/. Accessed April 29, 2026.
    Supports: 43% not recovered at 3 months, chronic joint symptom characteristics.

12. FDA. "FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Suspends Biologics License." August 22, 2025. https://www.fda.gov/safety/medical-product-safety-information/fda-update-safety-ixchiq-chikungunya-vaccine-live-fda-suspends-biologics-license-fda-safety.
    Supports: vaccine safety suspension details, serious adverse events including encephalitis and deaths.